RYTM.NASDAQRhythm Pharmaceuticals, INC

Form 4: Rhythm Pharmaceuticals Executive Pamela Cramer Reports Stock Transactions

Sentiment:

SEC Form 4 Filing

📋All filings for Rhythm Pharmaceuticals, INC
🔒Login to Follow

Pamela Cramer, Chief Human Resources Officer at Rhythm Pharmaceuticals, reports the acquisition and disposal of company stock and derivative securities.

Summary

  • Pamela Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
  • On February 16, 2025, Cramer exercised 3,300 Restricted Stock Units (RSUs) and acquired 3,300 shares of common stock.
  • On February 19, 2025, Cramer sold 982 shares of common stock at a price of $57.22 per share.
  • Cramer was also granted 20,000 Restricted Stock Units and 30,000 stock options on February 14, 2025.
  • The sale of shares was intended to cover withholding taxes related to the vesting of previously reported restricted stock units, pursuant to a Rule 10b5-1 plan adopted prior to February 27, 2023.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions. The sale was to cover taxes, and the grants are part of standard compensation. No strong positive or negative signals are present.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's future prospects. Form 4 filings are a standard part of regulatory compliance.

Comparison to Industry Standards

  • Executive compensation packages in the pharmaceutical industry often include stock options and restricted stock units to align management's interests with those of shareholders.
  • Vesting schedules for stock options and RSUs are typically structured to incentivize long-term employment and performance.
  • The use of Rule 10b5-1 plans is a common practice among corporate executives to manage stock sales and avoid accusations of insider trading.
  • Comparable companies such as Amgen, Biogen, and Vertex Pharmaceuticals also regularly report executive stock transactions via Form 4 filings.

Key Dates

DateDescription
February 27, 2023Date prior to which the Rule 10b5-1 instruction was adopted.
February 14, 2025Date of grant for 20,000 Restricted Stock Units and 30,000 stock options.
February 16, 2025Date of exercise of 3,300 Restricted Stock Units.
February 19, 2025Date of sale of 982 shares of common stock.
February 13, 2035Expiration date of the stock options granted on February 14, 2025.
February 14, 2026First vesting date for 25% of the 20,000 Restricted Stock Units granted on February 14, 2025.
February 16, 2026First vesting date for 25% of the 3,300 Restricted Stock Units exercised on February 16, 2025.
February 14, 2027Second vesting date for 25% of the 20,000 Restricted Stock Units granted on February 14, 2025.
February 16, 2027Second vesting date for 25% of the 3,300 Restricted Stock Units exercised on February 16, 2025.
February 14, 2028Third vesting date for 25% of the 20,000 Restricted Stock Units granted on February 14, 2025.
February 16, 2028Third vesting date for 25% of the 3,300 Restricted Stock Units exercised on February 16, 2025.
February 14, 2029Final vesting date for 25% of the 20,000 Restricted Stock Units granted on February 14, 2025.

Keywords

Form 4, Rhythm Pharmaceuticals, Pamela Cramer, Stock Options, Restricted Stock Units, Beneficial Ownership, RYTM, Stock Sale, Stock Transaction

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.